Cutaneous malignancy and human immunodeficiency virus disease

Wilkins, Karl; Turner, Ryan B.; Dolev, Jacqueline C.; LeBoit, Philip E.; Berger, Timothy G.; Maurer, Toby

doi:10.1016/j.jaad.2004.11.060

“…De maneira que o surgimento do mecanismo deve envolver ainda susceptibilidade genética ou exposição ambiental. 29 …”

Section: Discussionunclassified

Prevalência do herpes-vírus humano tipo 1 em neoplasias cutâneas epiteliais malignas

Ypiranga

¹

,

Moraes

²

2009

An. Bras. Dermatol.

1

0

View full text Add to dashboard Cite

Resumo: FUNDAMENTOS -O DNA viral pode atuar como oncogene, favorecendo o desenvolvimento de neoplasias, como as linfoides e da pele. Entre esses vírus, encontram-se alguns herpes-vírus humanos. OBJETIVO -Identificar a presença de DNA do herpes-vírus humano tipo 1 em neoplasias epiteliais pré-malignas, malignas e pele normal de indivíduos controle, avaliando seu papel na carcinogênese. MÉTODOS -Identificação, por reação em cadeia da polimerase, do DNA viral do tumor e pele sã de 41 pacientes e comparação com grupo controle, sem neoplasia. Análise estatística: Testes de Fisher e de McNemar. RESULTADOS -O vírus foi identificado em 20 indivíduos sem e em 21 com neoplasia. Destes últimos, 11 o expessaram apenas nas células tumorais. A diferença, entretanto, não foi estatisticamente significante. CONCLUSÕES -Parece não haver relação direta entre o encontro do DNA viral na pele sã e na pele tumoral. Sua presença pode facilitar o desenvolvimento da neoplasia ou apenas coincidir de se localizar onde esta já ocorreu. Palavras-chave: Herpes-vírus humano 1; Neoplasias cutâneas; Reação em cadeia de polimerase; Vírus oncogênicos Abstract: Background -Viral DNA may act as an oncogene, especially in skin and lymphoid organs. This group includes some human herpes virus. Objective -To identify human herpes virus type 1 DNA in pre-malignant and malignant skin samples of epithelial tumors comparing to normal skin to determine its role in carcinogenesis. Methods -Forty-one patients with epithelial tumors were submitted to biopsies from tumor and normal skin. The control group comprised 41 biopsies from patients with other dermatoses than cancer. After DNA extraction, polymerase chain reaction was performed to identify 199-bp band. The results were statistically evaluated by Fisher and McNemar tests. Results -The virus was identified in 20 subjects without cancer and in 21 with skin cancer. From these, 11 expressed it only in tumor cells. This difference was not significant. Conclusion -There seem to be no direct relation between viral findings in normal skin and skin cancer cells. It may act as a promoter or just coexist at the same site where a neoplastic transformation has already occurred.

show abstract

“…89 Multiple case studies also have reported malignant melanoma in HIV-infected patients, with melanoma at times exhibiting an aggressive course. 90,93 However, in such studies, multiple confounding factors exist, and the true influence of HIV-induced immunosuppression is difficult to ascertain. 89 Clinical Course in Patients With HIV Infection/AIDS The presence of immunosuppression may accelerate the progression of melanoma, especially in persons who already are predisposed to melanoma.…”

Section: Melanoma In Patients With Hiv Infection/aidsmentioning

confidence: 99%

“…89 Clinical Course in Patients With HIV Infection/AIDS The presence of immunosuppression may accelerate the progression of melanoma, especially in persons who already are predisposed to melanoma. 89,90,93,94 This logic seems to apply also to the population with HIV infection/AIDS. In one study, the disease-free survival and overall survival for HIV-infected patients with melanoma were significantly shorter than for the HIV-negative melanoma control group, with at least 40% of the HIV-positive melanoma patients dying of metastatic melanoma.…”

Section: Melanoma In Patients With Hiv Infection/aidsmentioning

confidence: 99%

Melanoma in Immunosuppressed Patients

Kubica

¹

,

Brewer

²

2012

Mayo Clinic Proceedings

View full text Add to dashboard Cite

The immunogenic characteristics of malignant melanoma are intriguing. To date, multiple studies exist regarding the immunogenicity of melanoma. In this article, we summarize data in the literature on the role of immunosuppression in melanoma and discuss several immunocompromised patient populations in detail. A comprehensive PubMed search was conducted with no date limitation. The following search terms were used: melanoma in combination with immunosuppression, immunocompromised, genetics, antigen processing, UV radiation, organ transplantation, organ transplant recipients, lymphoproliferative disease, lymphoma, CLL, NHL, radiation, and HIV/AIDS. Although no formal criteria were used for inclusion of studies, most pertinent studies on the topic were reviewed, with the exception of smaller case reports and case series. The included studies were generally large (Ն1000 patients in organ transplant recipient studies; Ն500 patients in lymphoma studies), with a focus on institutional experiences, or population-based national or international epidemiologic studies. Melanoma-induced immunosuppression, the role of UV radiation in melanoma development, and the epidemiology, clinical course, and prognosis of melanoma in immunocompromised patients are highlighted. Organ transplant recipients, patients with lymphoproliferative disorders, patients with iatrogenic immunosuppression, and patients with human immunodeficiency virus infection/AIDS are also highlighted. Recommendations are proposed for the care and monitoring of immunosuppressed patients with melanoma. With better understanding of the molecular microenvironment and clinical course of melanoma in immunosuppressed patients, novel therapies could be developed and outcomes potentially affected in these patients.

show abstract

“…89 Overall, patients with HIV infection have a 1.5-to 2-fold increased risk of malignancy. [89][90][91] Melanoma is one of these cancers, 91,92 with a standardized rate ratio of 2.6 (95% CI, 1.9-3.6). 89 Multiple case studies also have reported malignant melanoma in HIV-infected patients, with melanoma at times exhibiting an aggressive course.…”

Section: Melanoma In Patients With Hiv Infection/aidsmentioning

confidence: 99%

“…89 Multiple case studies also have reported malignant melanoma in HIV-infected patients, with melanoma at times exhibiting an aggressive course. 90,93 However, in such studies, multiple confounding factors exist, and the true influence of HIV-induced immunosuppression is difficult to ascertain. 89 …”

Section: Melanoma In Patients With Hiv Infection/aidsmentioning

confidence: 99%

Melanoma in immunosuppressed patients

Brewer

¹

2010

Expert Review of Dermatology

View full text Add to dashboard Cite

The immunogenic characteristics of malignant melanoma are intriguing. To date, multiple studies exist regarding the immunogenicity of melanoma. In this article, we summarize data in the literature on the role of immunosuppression in melanoma and discuss several immunocompromised patient populations in detail. A comprehensive PubMed search was conducted with no date limitation. The following search terms were used: melanoma in combination with immunosuppression, immunocompromised, genetics, antigen processing, UV radiation, organ transplantation, organ transplant recipients, lymphoproliferative disease, lymphoma, CLL, NHL, radiation, and HIV/AIDS. Although no formal criteria were used for inclusion of studies, most pertinent studies on the topic were reviewed, with the exception of smaller case reports and case series. The included studies were generally large (Ն1000 patients in organ transplant recipient studies; Ն500 patients in lymphoma studies), with a focus on institutional experiences, or population-based national or international epidemiologic studies. Melanoma-induced immunosuppression, the role of UV radiation in melanoma development, and the epidemiology, clinical course, and prognosis of melanoma in immunocompromised patients are highlighted. Organ transplant recipients, patients with lymphoproliferative disorders, patients with iatrogenic immunosuppression, and patients with human immunodeficiency virus infection/AIDS are also highlighted. Recommendations are proposed for the care and monitoring of immunosuppressed patients with melanoma. With better understanding of the molecular microenvironment and clinical course of melanoma in immunosuppressed patients, novel therapies could be developed and outcomes potentially affected in these patients.

show abstract

Cutaneous malignancy and human immunodeficiency virus disease

Cited by 129 publications

References 255 publications

Prevalência do herpes-vírus humano tipo 1 em neoplasias cutâneas epiteliais malignas

Prevalência do herpes-vírus humano tipo 1 em neoplasias cutâneas epiteliais malignas

Melanoma in Immunosuppressed Patients

Melanoma in immunosuppressed patients

Contact Info

Product

Resources

About